Cargando…

Immunity to SARS-CoV-2 up to 15 months after infection

Information concerning the longevity of immunity to SARS-CoV-2 following natural infection may have considerable implications for durability of immunity induced by vaccines. Here, we monitored the SARS-CoV-2 specific immune response in COVID-19 patients followed up to 15 months after symptoms onset....

Descripción completa

Detalles Bibliográficos
Autores principales:	Marcotte, Harold, Piralla, Antonio, Zuo, Fanglei, Du, Likun, Cassaniti, Irene, Wan, Hui, Kumagai-Braesh, Makiko, Andréll, Juni, Percivalle, Elena, Sammartino, Josè Camilla, Wang, Yating, Vlachiotis, Stelios, Attevall, Janine, Bergami, Federica, Ferrari, Alessandro, Colaneri, Marta, Vecchia, Marco, Sambo, Margherita, Zuccaro, Valentina, Asperges, Erika, Bruno, Raffaele, Oggionni, Tiberio, Meloni, Federica, Abolhassani, Hassan, Bertoglio, Federico, Schubert, Maren, Calzolai, Luigi, Varani, Luca, Hust, Michael, Xue, Yintong, Hammarström, Lennart, Baldanti, Fausto, Pan-Hammarström, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8736281/ https://www.ncbi.nlm.nih.gov/pubmed/35018336 http://dx.doi.org/10.1016/j.isci.2022.103743

Ejemplares similares

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
por: Zuo, Fanglei, et al.
Publicado: (2022)

Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection
por: Sherina, Natalia, et al.
Publicado: (2021)

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1
por: Zuo, Fanglei, et al.
Publicado: (2023)

SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay
por: Cassaniti, Irene, et al.
Publicado: (2021)

Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit
por: Colaneri, M., et al.
Publicado: (2020)

Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study
por: Cassaniti, Irene, et al.
Publicado: (2022)

Impact of Viral Decontamination Method on Cytokine Profile of COVID-19 Patients
por: Magrì, Davide, et al.
Publicado: (2021)

Evaluation of the Neutralizing Antibodies Response against 14 SARS-CoV-2 Variants in BNT162b2 Vaccinated Naïve and COVID-19 Positive Healthcare Workers from a Northern Italian Hospital
por: Sammartino, Josè Camilla, et al.
Publicado: (2022)

Design, structure and plasma binding of ancestral β-CoV scaffold antigens
por: Hueting, David, et al.
Publicado: (2023)

Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers
por: Bergami, Federica, et al.
Publicado: (2022)

Antibody therapy for COVID-19
por: Hammarström, Lennart, et al.
Publicado: (2021)

Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant
por: Schubert, Maren, et al.
Publicado: (2022)

Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients—a perspective
por: Hammarström, Lennart, et al.
Publicado: (2020)

Real-life lack of evidence of viable SARS-CoV-2 transmission via inanimate surfaces: The SURFACE study
por: Sammartino, José Camilla, et al.
Publicado: (2023)

Macrophages and Monocytes: “Trojan Horses” in COVID-19
por: Percivalle, Elena, et al.
Publicado: (2021)

Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients
por: Cassaniti, Irene, et al.
Publicado: (2022)

SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers
por: Rovida, Francesca, et al.
Publicado: (2021)

Molecular Epidemiology of Rhinovirus/Enterovirus and Their Role on Cause Severe and Prolonged Infection in Hospitalized Patients
por: Giardina, Federica A. M., et al.
Publicado: (2022)

Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant
por: Cassaniti, Irene, et al.
Publicado: (2021)

SARS-CoV-2 positivity in rectal swabs: implication for possible transmission
por: Novazzi, Federica, et al.
Publicado: (2020)

HBV and HDV: New Treatments on the Horizon
por: Zuccaro, Valentina, et al.
Publicado: (2021)

Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy
por: Colaneri, M., et al.
Publicado: (2020)

SARS-CoV-2–specific B- and T-cell immunity in a population-based study of young Swedish adults
por: Björkander, Sophia, et al.
Publicado: (2022)

Dynamic NLR and PLR in Predicting COVID-19 Severity: A Retrospective Cohort Study
por: Asperges, Erika, et al.
Publicado: (2023)

Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up
por: Lasagna, Angioletta, et al.
Publicado: (2023)

SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment
por: Ferrari, Alessandro, et al.
Publicado: (2022)

Thirteen Years of Phleboviruses Circulation in Lombardy, a Northern Italy Region
por: Percivalle, Elena, et al.
Publicado: (2021)

Hallmarks of Cancers: Primary Antibody Deficiency Versus Other Inborn Errors of Immunity
por: Abolhassani, Hassan, et al.
Publicado: (2021)

SARS-CoV-2 infection in patients with inborn errors of immunity due to DNA repair defects: DNA repair deficiency and COVID19
por: Wang, Yating, et al.
Publicado: (2022)

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
por: Lasagna, A., et al.
Publicado: (2022)

Impact of Pneumococcal Urinary Antigen Testing in COVID-19 Patients: Outcomes from the San Matteo COVID-19 Registry (SMACORE)
por: Valsecchi, Pietro, et al.
Publicado: (2021)

SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
por: Kim, Eun, et al.
Publicado: (2023)

mRNA BNT162b Vaccine Elicited Higher Antibody and CD4(+) T-Cell Responses than Patients with Mild COVID-19
por: Zavaglio, Federica, et al.
Publicado: (2022)

Assessing the Efficacy of Early Therapies against SARS-CoV-2 in Hematological Patients: A Real-Life Study from a COVID-19 Referral Centre in Northern Italy
por: Colaneri, Marta, et al.
Publicado: (2022)

Performance of Whole Blood Stimulation Assays for the Quantification of SARS-CoV-2 Specific T-Cell Response: A Cross-Sectional Study
por: Bergami, Federica, et al.
Publicado: (2022)

Adapting Neutralizing Antibodies to Viral Variants by Structure‐Guided Affinity Maturation Using Phage Display Technology
por: Peissert, Frederik, et al.
Publicado: (2023)

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
por: Lasagna, A., et al.
Publicado: (2022)

Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
por: Lasagna, A., et al.
Publicado: (2022)

Genetic divergence of influenza A NS1 gene in pandemic 2009 H1N1 isolates with respect to H1N1 and H3N2 isolates from previous seasonal epidemics
por: Campanini, Giulia, et al.
Publicado: (2010)

Authors’ response: COVID-19: how accurate are seroprevalence studies?
por: Cassaniti, Irene, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ae3uggmsehgo8mh5o0shgg5evn